Comparison of the efficacy of oral progestogens in the management of threatened miscarriage

A randomized controlled trial comparing the efficacy of oral progestogens in the management of threatened miscarriage - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055743

Enrollment

121

Registered

2023-07-26

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O268- Other specified pregnancy relatedconditions

Interventions

Intervention1: Oral micronized progesterone sustained release: Oral micronized progesterone sustained release 400 mg at once daily dosing starting from the period of detection of threatened miscarriag

Eligibility

Inclusion criteria

Inclusion criteria: Period of gestation between 6-16 weeks presenting with threatened miscarriage (with or without the history of 1/more abortion of unknown etiology) confirmed by dating scan. 3. Confirmed intra uterine live pregnancy (by means of ultrasonography)

Exclusion criteria

Exclusion criteria: Age of women older than 40 years, IVF pregnancy Multifoetal pregnancy Pregnancy with any condition that can explain her present miscarriage

Design outcomes

Primary

Measure	Time frame
Oral natural micronized progesterone sustained release is non inferior to dydrogesterone in the management of threatened miscarriage in 121 antenatal patientsTimepoint: Till 28 weeks of gestation or the time of delivery (whether complete abortion or live birth)	—

Secondary

Measure	Time frame
To assess the efficacy of oral progestogens in threatened miscarriage.Timepoint: From 28 weeks of period of gestation or upto the period of gestation at the time of delivery whether live birth or abortion	—

Countries

India

Contacts

Public ContactDr Bidisha Banerjee

Vivekananda institute of medical sciences

sajaldat@gmail.com9830065242

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026